Grâce à un programme de remboursement organisé en collaboration avec le Kankerfonds du Limbourg, InnoSer a récemment fait l’acquisition de deux nouveaux appareils d’imagerie qui permettront d’approfondir les connaissances sur nos plateformes in vitro et in vivo destinées à la recherche préclinique en oncologie. Le premier est l’l’ImageXpress Micro 4, unesolution d’imagerie de cellules vivantes à haut contenu, et le second est le système d’imagerie in vivo Lumina III, qui permet l’imagerie bioluminescente (BLI) de modèles in vivo.
ImageXpress Micro 4 –
Lumina III In Vivo Imaging System –
Envie d'en savoir plus ?
How do you build the right immunotoxicity assessment strategy for your nonclinical safety GLP program?
From standard toxicity studies and follow-up immune-function testing to immunogenicity assessment, test-system selection, and GLP execution, this article explores how to build an effective immunotoxicity assessment strategy for biotechnology-derived therapeutics.The...
Neurodevelopmental disorder mouse models at InnoSer — TSC, Rett & STXBP1
in this month's update, we invite you to explore recent developments in rare neurodevelopmental disorders associated with epilepsy and seizure phenotypes. We highlight emerging therapeutic approaches, discuss the importance of selecting translationally relevant...
Your compound has shown efficacy in a preclinical disease model – now what? Moving from exploratory studies to GLP toxicology studies
A practical guide to transitioning from exploratory studies to GLP toxicology when outsourcing your non-clinical safety program to a specialist GLP toxicology CRO.Demonstrating efficacy in a disease model represents a major milestone in preclinical drug development....




